期刊
ARTHRITIS AND RHEUMATISM
卷 58, 期 6, 页码 1810-1822出版社
WILEY
DOI: 10.1002/art.23501
关键词
-
类别
资金
- NCRR NIH HHS [M01-RR-06192, M01-RR-01070, M01 RR000032, UL1 RR024148, M01 RR020359, M01 RR001070, M01-RR-00032, M01 RR006192, M01 RR001066, M01-RR-00211, M01-RR-020359, M01 RR000211, UL-1-RR-024148] Funding Source: Medline
- NIAMS NIH HHS [R01 AR045255, N01-AR-902242, K24 AR002224, U01 AR051874, K24-AR-2224-01A1, P50-AR-044890-55, P50 AR044890] Funding Source: Medline
- PHS HHS [M01-RRO-00533] Funding Source: Medline
Objective. To investigate the safety and efficacy of oral bovine type I collagen (CI) treatment in patients who have had diffuse cutaneous systemic sclerosis (dc-SSc; scleroderma) for <= 10 years. Methods. One hundred sixty-eight patients with dcSSc were enrolled in a double-blind, placebo-controlled trial of oral CI (500 mu g/day) or placebo administered over 12 months, with a followup visit at month 15. The primary outcome was the modified Rodnan skin thickness score (MRSS). Other clinical and immune system parameters were also assessed. Results. Intent-to-treat and modified intent-to-treat analyses showed that for the total population of patients with dcSSc, there were no significant differences in the mean change in MRSS or other key clinical parameters between the CI and placebo treatment groups at 12 months or at 15 months. However, in a subanalysis of the available data at month 15, the Cl-treated group of patients with late-phase dcSSc experienced a significant reduction in the MRSS compared with that in the placebo-treated patients with late-phase dcSSc (change in MRSS at month 15-7.9 versus -2.9; P = 0.0063). Conclusion. Although the results from this trial did not meet the primary outcome goals, the findings from exploratory analyses indicated that CI treatment may benefit patients with late-phase dcSSc. This new treatment strategy and preliminary clinical observations in patients with dcSSc need to be corroborated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据